Roche fee boosts Biomatrix revenue in 1994
This article was originally published in Clinica
Executive Summary
Biomatrix has received a $5 million fee from Roche-Syntex for expanded European marketing rights to Biomatrix' hylan polymer, Synvisc, for osteoarthritis.